Since tumor PD-L1 expression significantly influences the response of patients to immunotherapy, we conducted an initial verification of the correlation between serum FLT3LG expression and PD-L1 expression in clinical tumor tissue samples. The gene discussed is FLT3LG; the disease is neoplasm.